Insider Selling: CRISPR Therapeutics (NASDAQ:CRSP) CEO Sells 10,020 Shares of Stock

CRISPR Therapeutics AG (NASDAQ:CRSP) CEO Samarth Kulkarni sold 10,020 shares of the company’s stock in a transaction on Monday, March 23rd. The stock was sold at an average price of $46.78, for a total transaction of $468,735.60. Following the completion of the sale, the chief executive officer owned 255,501 shares of the company’s stock, valued at approximately $11,952,336.78. The trade was a 3.77% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Samarth Kulkarni also recently made the following trade(s):

• On Monday, March 16th, Samarth Kulkarni sold 10,349 shares of CRISPR Therapeutics stock. The shares were sold at an average price of $48.26, for a total transaction of $499,442.74.
• On Wednesday, March 11th, Samarth Kulkarni sold 9,798 shares of CRISPR Therapeutics stock. The shares were sold at an average price of $52.80, for a total value of $517,334.40.
• On Thursday, February 19th, Samarth Kulkarni sold 6,967 shares of CRISPR Therapeutics stock. The shares were sold at an average price of $52.58, for a total value of $366,324.86.
• On Tuesday, January 20th, Samarth Kulkarni sold 30,000 shares of CRISPR Therapeutics stock. The shares were sold at an average price of $51.75, for a total transaction of $1,552,500.00.
• On Thursday, January 22nd, Samarth Kulkarni sold 60,000 shares of CRISPR Therapeutics stock. The stock was sold at an average price of $60.23, for a total transaction of $3,613,800.00.

CRISPR Therapeutics Trading Down 1.0%

Shares of NASDAQ CRSP opened at $46.43 on Wednesday. The firm has a market cap of $4.46 billion, a price-to-earnings ratio of -7.12 and a beta of 1.72. CRISPR Therapeutics AG has a 1-year low of $30.04 and a 1-year high of $78.48. The stock has a fifty day simple moving average of $52.89 and a two-hundred day simple moving average of $57.02.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Thursday, February 12th. The company reported ($1.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.15) by ($0.22). The firm had revenue of $0.86 million during the quarter, compared to the consensus estimate of $4.72 million. CRISPR Therapeutics had a negative net margin of 16,569.77% and a negative return on equity of 26.31%. The company’s revenue was down 97.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.01) earnings per share. Analysts forecast that CRISPR Therapeutics AG will post -5.16 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Mcguire Capital Advisors Inc. bought a new stake in shares of CRISPR Therapeutics during the 4th quarter valued at $25,000. Ramirez Asset Management Inc. purchased a new stake in CRISPR Therapeutics during the 4th quarter valued at about $26,000. Rothschild Investment LLC grew its holdings in shares of CRISPR Therapeutics by 836.7% during the fourth quarter. Rothschild Investment LLC now owns 562 shares of the company’s stock valued at $29,000 after buying an additional 502 shares during the last quarter. Thurston Springer Miller Herd & Titak Inc. increased its position in shares of CRISPR Therapeutics by 196.9% during the fourth quarter. Thurston Springer Miller Herd & Titak Inc. now owns 576 shares of the company’s stock valued at $30,000 after acquiring an additional 382 shares in the last quarter. Finally, Thompson Investment Management Inc. bought a new stake in shares of CRISPR Therapeutics in the 3rd quarter worth $33,000. Hedge funds and other institutional investors own 69.20% of the company’s stock.

Analyst Upgrades and Downgrades

CRSP has been the topic of a number of recent analyst reports. Morgan Stanley reissued an “underweight” rating and issued a $33.00 price target on shares of CRISPR Therapeutics in a report on Tuesday, February 17th. Bank of America dropped their target price on shares of CRISPR Therapeutics from $90.00 to $89.00 and set a “buy” rating for the company in a research report on Thursday, January 22nd. Citizens Jmp cut their price objective on CRISPR Therapeutics from $86.00 to $80.00 and set a “market outperform” rating for the company in a report on Friday, January 30th. Chardan Capital increased their target price on shares of CRISPR Therapeutics from $74.00 to $76.00 and gave the company a “buy” rating in a report on Saturday, February 14th. Finally, Needham & Company LLC raised their price target on CRISPR Therapeutics from $80.00 to $82.00 and gave the stock a “buy” rating in a research report on Friday, February 13th. Ten analysts have rated the stock with a Buy rating, six have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, CRISPR Therapeutics presently has an average rating of “Hold” and a consensus target price of $64.53.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.